我要投票 中生方政NBF在医疗器械行业中的票数:1207
· 外 推 电 报 ·
2026-01-09 09:01:34 星期五

【中生方政NBF是哪个国家的品牌?】

中生方政NBF是什么牌子?「中生方政NBF」是 中生方政生物技术股份有限公司 旗下著名品牌。该品牌发源于江苏省泰州市,由创始人郭光华在2009-09-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生方政NBF品牌出海!将品牌入驻外推网,定制中生方政NBF品牌推广信息,可以显著提高中生方政NBF产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

中生方政生物技术股份有限公司,成立于2009年,是一家集诊断试剂、生物医药、预防性疫苗及仪器设备的研发和生产为一体的生物医药技术企业。占地面积近55000平方米,建筑面积25700 平方米。研发总部设立在美国,主要从事具有国际前沿技术水平的体外诊断试剂的开发和研制。已建成核酸分子诊断试剂生产车间、金标车间、酶联免疫诊断试剂生产车间、中试(设备)车间、动力中心、动物实验楼、综合楼(研发中心)等标准化GMP生产车间及现代化办公配套设施,现已完成规模化产业基地的建设,形成了年产分子诊断试剂1000万人份和分子检测设备1000台的生产能力。

中生方政长期专注于临床分子诊断技术的开发。在国内IVD行业,中生方政是为数不多拥6项以上注册文号的生产企业,实现了产品价格多层次化,产品结构梯队化,可以满足不同客户的检测需求和价格承受能力,具有较宽的市场辐射面,为市场纵深开发打下了良好基础。

作为前沿技术创新主导型高科技企业,公司依托自主研发及联合开发等多种方式,创建了成熟稳定的新型核酸检测技术平台,并已先期开发出人乳头瘤病毒(HPV)临床检测试剂,成为国内首个利用恒温技术检测HPV病毒的产品。目前公司已获得国家食品药品监督总局颁发的15种型别人乳头瘤病毒和16/18型人乳头瘤病毒核酸检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)基因分型检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)核酸检测试剂盒(恒温扩增-荧光法)等产品注册证书。同时,公司还开发出配套的恒温荧光检测设备。依托于该技术平台,公司正在努力拓展产品线,逐步推进试剂和仪器的“系列化”、“一体化”发展目标。

中生方政将本着“用心、专注、创新、服务”的企业理念和“成为国内在体外诊断试剂产业领域最具创新研发能力的优秀产品与服务供应商”的发展愿景,“资本加创新”双轮驱动的发展战略,以及“质量第一 追求卓越”的管理理念,愿同社会各界合作共赢,回馈股东、客户和员工,进而为推动我国医学检验产业及健康医疗事业的发展做出新的贡献。


英文翻译:Zhongsheng Fangzheng Biotechnology Co., Ltd., founded in 2009, is a biomedical technology enterprise integrating research and development and production of diagnostic reagents, biomedicine, preventive vaccines and equipment. It covers an area of nearly 55000 square meters and a building area of 25700 square meters. R & D headquarters is established in the United States, mainly engaged in the development and development of in vitro diagnostic reagents with international cutting-edge technology level. Standardized GMP production workshops and modern office facilities have been built, such as nucleic acid molecular diagnostic reagent production workshop, gold standard workshop, enzyme-linked immunodiagnostic reagent production workshop, pilot test (equipment) workshop, power center, animal laboratory building, comprehensive building (R & D center). The construction of large-scale industrial base has been completed, with an annual output of 10 million people and molecules of molecular diagnostic reagents Production capacity of 1000 testing equipment. Zhongsheng Fangzheng has long focused on the development of clinical molecular diagnosis technology. In the domestic IVD industry, Zhongsheng Fangzheng is one of the few manufacturers with more than 6 registered numbers. It has realized multi-level product price and echelon product structure, which can meet the testing needs and price tolerance of different customers. It has a wide market radiation and lays a good foundation for in-depth market development. As a leading high-tech enterprise of cutting-edge technology innovation, the company has established a mature and stable new nucleic acid detection technology platform relying on independent research and development and joint development, and has developed the clinical detection reagent of human papillomavirus (HPV) in advance, becoming the first domestic product using constant temperature technology to detect HPV virus. At present, the company has obtained product registration certificates issued by the State Food and drug administration, such as 15 types of HPV and 16 / 18 HPV nucleic acid detection kits (constant temperature amplification fluorescence method), HPV gene typing detection kits (constant temperature amplification fluorescence method), HPV nucleic acid detection kits (constant temperature amplification fluorescence method), etc Book. At the same time, the company also developed a complete set of constant temperature fluorescence detection equipment. Relying on this technology platform, the company is striving to expand its product line and gradually promote the development goals of "serialization" and "integration" of reagents and instruments. Zhongsheng Fangzheng is willing to cooperate with all walks of life for win-win cooperation and feedback with the corporate philosophy of "heart, focus, innovation and service", the development vision of "becoming the best product and service provider with the most innovative R & D ability in the field of in vitro diagnostic reagent industry in China", the development strategy of "capital plus innovation" driven by two wheels, and the management concept of "quality first pursuit of excellence" Shareholders, customers and employees will make new contributions to the development of China's medical testing industry and health care industry.

本文链接: https://www.waitui.com/brand/2c7dece2d.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

华纳兄弟探索公司拒绝派拉蒙,坚持与Netflix的交易

华纳兄弟探索公司敦促股东拒绝派拉蒙的敌意收购,并重申其将工作室和流媒体资产出售给Netflix的协议是更优报价,且完成路径更明确。(新浪财经)

2小时前

Grok因涉性图像面临审查

埃隆·马斯克麾下未上市企业xAI在其Grok模型被用于生成涉性图像(包括未成年人图像)后受到抨击,这引发了监管机构对该与X平台集成的工具的调查和政策质疑。(新浪财经)

2小时前

保险公司发债规模连续三年超千亿元,多重因素推动

连续三年,保险公司发行债券规模超千亿元。刚刚过去的2025年,23家保险公司发债规模合计达1042亿元。业内人士普遍认为,这背后有多重推动因素——低利率周期下,保险公司普遍面临较高的资本补充需求;利率下行,发债成本更低,险企有动力发新债置换旧债;也有险企希望在利率低位时融资以进一步夯实资本实力、增厚发展安全垫。另外,在逆周期监管思路下,保险公司发债也在一定程度上获得了监管部门的支持。(证券时报)

2小时前

中信建投:白酒板块迎来周期底部配置机会

36氪获悉,中信建投指出,白酒产业“五底阶段”(政策底、库存底、动销底、批价底、产销底)与资本市场“三低一高”(预期低、估值低、公募持仓低、高分红)共振,结合近期市场策略相继落地,站在春节旺季来临之际,认为本轮白酒调整期拐点将至,资本市场预期先行,白酒板块迎来周期底部配置机会。

2小时前

CrowdStrike以7.4亿美元收购身份安全初创公司SGNL

网络安全提供商CrowdStrike周四宣布,将以近7.4亿美元的价格收购身份管理初创公司SGNL,以在人工智能网络攻击时代加强防御。该公司表示,此次收购将帮助CrowdStrike的Falcon云安全平台用户更好地管理人员和人工智能身份访问请求以及实时风险。该交易预计将于2027财年第一季度完成。(新浪财经)

2小时前

本页详细列出关于中生方政NBF的品牌信息,含品牌所属公司介绍,中生方政NBF所处行业的品牌地位及优势。
咨询